Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
23.97B
Market cap23.97B
Price-Earnings ratio
-7.49
Price-Earnings ratio-7.49
Dividend yield
Dividend yield
Average volume
9.17M
Average volume9.17M
High today
$62.75
High today$62.75
Low today
$59.85
Low today$59.85
Open price
$60.99
Open price$60.99
Volume
11.70M
Volume11.70M
52 Week high
$67.74
52 Week high$67.74
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 23.97B, Moderna(MRNA) trades at $60.63. The stock has a price-to-earnings ratio of -7.49.

On 2026-06-24, Moderna(MRNA) stock traded between a low of $59.85 and a high of $62.75. Shares are currently priced at $60.63, which is +1.3% above the low and -3.4% below the high.

Moderna(MRNA) shares are trading with a volume of 11.7M, against a daily average of 9.17M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $67.74 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $67.74 and a 52-week low of $22.28.

MRNA News

Simply Wall St 1d
Moderna Is Up 10.1% After Unanimous FDA Panel Backing For mRNA Flu Shot mFlusiva

An FDA advisory committee previously voted unanimously to recommend approval of Moderna’s mRNA-based influenza vaccine, mFlusiva, for adults aged 50 and over, a...

Moderna Is Up 10.1% After Unanimous FDA Panel Backing For mRNA Flu Shot mFlusiva
Nasdaq 2d
Should You Buy Moderna Before Aug. 5?

Key Points Investors flocked to Moderna during early pandemic days as its coronavirus vaccine delivered blockbuster revenue. Since, times have been tough for...

Should You Buy Moderna Before Aug. 5?
Barron's 2d
Moderna Stock’s 6-Day Rally Ends in a Dive. Why It’s One of the S&P 500’s Biggest Losers Today.

Biotech and Pharma Moderna Stock’s 6-Day Rally Ends in a Dive. Why It’s One of the S&P 500’s Biggest Losers Today. In this article MRNA SPX Moderna stock rallie...

Moderna Stock’s 6-Day Rally Ends in a Dive. Why It’s One of the S&P 500’s Biggest Losers Today.

Analyst ratings

67%

of 27 ratings
Buy
14.8%
Hold
66.7%
Sell
18.5%

More MRNA News

TipRanks 4d
Moderna Stock Jumps as Pipeline Hype Outruns Wall Street

Moderna ( (MRNA) ) has risen by 22.69%. Read on to learn why. Claim 55% Off TipRanks Unlock powerful investing tools and data-driven insights with TipRanks Prem...

Nasdaq 5d
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

Key Points Modera grew revenue by 260% year over year in the first quarter. The company is trying its mRNA platform in oncology vaccines. Moderna is looking...

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?
Benzinga 6d
Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0

The FDA’s Vaccines and Related Biological Products Advisory Committee, or VRBPAC, voted 9-0 that the benefits of Moderna’s investigational flu vaccine mRNA-1010...

Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0
The Wall Street Journal 6d
FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine

The FDA plans to consider the committee’s recommendations as part of its ongoing review of Moderna’s biologics license application for mRNA-1010, Moderna said....

FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine
TipRanks 6d
Moderna announces FDA advisory committee votes in favor of mRNA-1010

Moderna (MRNA) announced that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of...

TipRanks 6d
Jefferies’ confidence in Moderna’s mRNA flu shot rises after AdCom support

Jefferies reiterated a Hold rating and $45 price target on Moderna (MRNA) after the FDA’s Advisory Committee voted 9-0 in favor of a full approval for Moderna’s...

Nasdaq 7d
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Key Points Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area. AMD i...

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.